Healthequity (NASDAQ:HQY) had its price target hoisted by equities research analysts at Cantor Fitzgerald from $83.00 to $90.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 6.50% from the stock’s previous close.
A number of other equities analysts also recently weighed in on HQY. BidaskClub downgraded shares of Healthequity from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. Zacks Investment Research downgraded shares of Healthequity from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. ValuEngine downgraded shares of Healthequity from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 5th. SunTrust Banks downgraded shares of Healthequity from a “buy” rating to a “hold” rating and cut their price target for the stock from $105.00 to $90.00 in a report on Thursday, December 6th. Finally, Wells Fargo & Co cut their price target on shares of Healthequity from $100.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, December 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $86.85.
NASDAQ HQY opened at $84.51 on Tuesday. Healthequity has a 1 year low of $50.29 and a 1 year high of $101.58. The firm has a market capitalization of $5.27 billion, a PE ratio of 88.96, a PEG ratio of 2.78 and a beta of 1.72.
Healthequity (NASDAQ:HQY) last issued its quarterly earnings results on Monday, March 18th. The company reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.06. The company had revenue of $75.78 million for the quarter, compared to the consensus estimate of $74.28 million. Healthequity had a net margin of 25.73% and a return on equity of 13.97%. The firm’s quarterly revenue was up 25.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.09 EPS. On average, research analysts expect that Healthequity will post 1.03 earnings per share for the current year.
In related news, VP Darcy G. Mott sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $60.28, for a total value of $241,120.00. Following the transaction, the vice president now directly owns 82,000 shares in the company, valued at $4,942,960. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Delano Ladd sold 6,875 shares of the company’s stock in a transaction that occurred on Wednesday, February 20th. The stock was sold at an average price of $78.00, for a total transaction of $536,250.00. Following the completion of the transaction, the executive vice president now owns 14,340 shares in the company, valued at $1,118,520. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,875 shares of company stock worth $1,332,090. Insiders own 4.00% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in Healthequity by 10.6% during the fourth quarter. Geode Capital Management LLC now owns 627,359 shares of the company’s stock valued at $37,421,000 after acquiring an additional 60,027 shares during the last quarter. Norges Bank bought a new position in Healthequity during the fourth quarter valued at approximately $29,950,000. O Brien Greene & Co. Inc bought a new position in Healthequity during the fourth quarter valued at approximately $203,000. Dimensional Fund Advisors LP grew its position in Healthequity by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 505,825 shares of the company’s stock valued at $30,171,000 after acquiring an additional 8,813 shares during the last quarter. Finally, Amalgamated Bank grew its position in Healthequity by 129.9% during the fourth quarter. Amalgamated Bank now owns 8,501 shares of the company’s stock valued at $507,000 after acquiring an additional 4,804 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading: What is a Roth IRA?
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.